Description
Cardiogen Peptide
Cardiogen is considered to be a peptide bioregulator, possibly affecting fibroblasts and causing scar formation and tissue repair. The peptide has been widely researched for its potential to mitigate cardiovascular issues. Still, recent research has suggested that it may also be functional in other tissues via influencing fibroblast activities. Furthermore, scientists believe Cardiogen is synergistic, with additional studies in mouse models indicating that the peptide may increase tumor cell apoptosis.
Chemical Makeup(1)
Molecular Formula: C18H31N7O9
Molecular Weight: 489.5 g/mol
PubChem CID: 11583989
Synonyms: SCHEMBL3194515
IUPAC Condensed: H-Ala-Glu-Asp-Arg-OH
Research and Clinical Studies
Cardiogen Peptide and Cancer Research
The peptide is considered by researchers to be an apoptotic reductant in cardiac cells, via possibly decreasing p53 expression, and may exhibit opposite impacts on tumor cells. The p53 gene produces a protein found inside the nucleus of cells and is considered essential in controlling cell division and cell death. An experiment was conducted on mice with M-1 Sarcoma (indicating it has metastasized to other body tissues and organs) to determine the tumor-modulating potential of Cardiogen, with apoptosis on tumor cells exceeding normal levels and considered uncontrollable.(2) The results indicated a consequence of necrotic and hemorrhagic development and the improvement of tumor cell apoptosis. The results of the experiment suggested that:
‘The dose-dependent inhibition of M-1 sarcoma growth after […] cardiogen was caused by the development of hemorrhagic necrosis and stimulation of tumor cell apoptosis. The parameters of proliferative activity indicate that inhibition of tumor growth was not caused by the direct cytostatic effect of the drug on the tumor. Morphological signs indicate a specific mechanism of cardiogen action, realized through the vascular network of the tumor’. (2)
The supposed proliferative action of the peptide suggests that tumor growth inhibition is not the result of a cytostatic compound on the tumor. According to morphology, tumor growth inhibition may be mediated by a specific peptide mechanism of action. This event may be particular to some tumor cells due to their atypical and increased vascular supply, which supports the researchers’ theory that Cardiogen may be a valuable adjunct in cancer research.
Cardiogen Peptide and Prostate Cancer
According to clinical researchers, Cardiogen may significantly increase the expression of signaling factors involved in the differentiation of prostate fibroblasts while also possibly decreasing synthesis in senescent cultures.(3) Because these signaling factors are considered to promote the development and progression of prostate cancer, they may be inhibited in aging and senescent fibroblasts. This inhibition would support why prostate cancer is common in the elderly but rarely found in the young. Here, the peptide is suggested by study findings to actively influence the signaling factors, potentially bringing them to normal levels or better than those seen in young cell cultures.
Cardiogen Peptide and Cardiomyocytes
Cardiogen has been suggested by researchers to increase cardiomyocyte proliferation while possibly decreasing fibroblast growth and development and scar formation, resulting in potential long-term and improved cardiac remodeling. Studies suggest that Cardiogen may reduce the expression of the p53 gene, resulting in a lower apoptosis rate.(4, 5) Researchers propose Cardiogen’s potential in cardial tissue:
‘The tetrapeptide cardiogen demonstrated the great stimulating effect on the proliferation both in tissues from young and old rats. The immunohistochemical study demonstrated a decrease of the p53 protein expression by cardiogen action. This fact can testify that cardiogen inhibits the apoptosis process in the myocardial tissue’.(5)
Cardiogen peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.
References
- https://pubchem.ncbi.nlm.nih.gov/compound/Cardiogen-82
- Levdik NV, Knyazkin IV. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med. 2009 Sep;148(3):433-6. English, Russian
- Kheĭfets OV, Poliakova VO, Kvetnoĭ IM. [Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging]. Adv Gerontol. 2010;23(1):68-70
- Grieco P, Gomez-Monterrey I. Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials. Arch Biochem Biophys. 2019 Feb 15;662:15-32. doi: 10.1016/j.abb.2018.11.021
- N. I. Chalisova et al., “[The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats],” Adv. Gerontol. Uspekhi Gerontol., vol. 22, no. 3, pp. 409–413, 2009
NOTE: These products are intended for laboratory research use only. Cardiogen for sale (20mg) is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
